Omega Healthcare Investors Inc. priced its public offering of 7.5 million common shares under a planned forward sale agreement.
The offering is expected to result in gross proceeds of roughly $300 million.
The forward purchaser, BofA Merrill Lynch or its affiliate, has granted underwriters a 30-day option acquire up to an additional 1,125,000 shares.
BofA Merrill Lynch or its affiliate is expected to borrow from third parties and sell the shares to the underwriters.
The net proceeds, if any, are marked for financing pending acquisitions, with any remaining proceeds to be used for general corporate purposes, including repaying debt and funding other potential acquisition, development and investment opportunities.
BofA Merrill Lynch is acting as sole book runner for the offering.
